Cyclopropanes

Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery

Retrieved on: 
Monday, April 20, 2020
Medical specialties, Surgery, Medicine, Cardiac surgery, Alcohols, AstraZeneca, Cyclopropanes, Ticagrelor, Cardiothoracic surgery, Emergency Use Authorization, Food and Drug Administration, Cardiopulmonary bypass

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification.

Key Points: 
  • CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification.
  • These are conditions where the risk of death is extremely high, yet no effective treatments exist.
  • CytoSorb has received FDA Emergency Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.
  • CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

Retrieved on: 
Monday, March 30, 2020
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Other Health, Chemical compounds, Drugs, Organic compounds, Cyclopropanes, Alcohols, AstraZeneca, Ticagrelor, Aspirin

BRILINTA is not indicated for use without aspirin or in patients undergoing PCI who have not had an ACS event.

Key Points: 
  • BRILINTA is not indicated for use without aspirin or in patients undergoing PCI who have not had an ACS event.
  • BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
  • When possible, interrupt therapy with BRILINTA for 5 days prior to surgery that has a major risk of bleeding.
  • The TWILIGHT subgroup analyses evaluated patients with diabetes (TWILIGHT-DM) and patients who had successfully undergone a complex PCI (TWILIGHT-COMPLEX).

Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma

Retrieved on: 
Wednesday, March 25, 2020
Oncology, Health, Other Science, Clinical trials, Research, Science, Biotechnology, Branches of biology, Tyrosine kinase inhibitors, Cyclopropanes, Quinolines, Medicine, Clinical medicine, Antineoplastic drugs, Exelixis, Cabozantinib, Ipsen, Angiology, Renal cell carcinoma

In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.

Key Points: 
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.
  • Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough

Retrieved on: 
Tuesday, March 17, 2020
Biotechnology, General Health, Health, Pharmaceutical, Clinical trials, Chemical compounds, Drugs, Organic compounds, Cyclopropanes, NMDA receptor antagonists, Antidepressants, Piperidines, Prostaglandins, Setipiprant, Naldemedine, COUGH-1 and COUGH-2, Gefapixant, Chronic Cough, Merck

The gefapixant 15 mg twice daily treatment arms did not meet the primary efficacy endpoint in either Phase 3 study.

Key Points: 
  • The gefapixant 15 mg twice daily treatment arms did not meet the primary efficacy endpoint in either Phase 3 study.
  • The safety and tolerability profile of gefapixant during the trials to date is consistent with the previously reported Phase 2 study.
  • COUGH-1 (NCT03449134) and COUGH-2 (NCT03449147) are international Phase 3, randomized, double-blind, placebo-controlled, studies to evaluate the efficacy and safety of gefapixant in reducing cough frequency in adult participants with refractory or unexplained chronic cough.
  • Gefapixant is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough.

Nicox’s Partner Secures Additional Approval of VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan

Retrieved on: 
Monday, March 9, 2020
Organic compounds, Chemical compounds, RTT, Prostaglandins, Triols, Ophthalmology, Contact lenses, NicOx, Cyclopropanes, Latanoprostene bunod, Bausch & Lomb, Lomb

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan.
  • VYZULTA is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension and is commercialized in the U.S. and Canada.
  • Nicox receives increasing tiered net royalties of 6% to 12% on global sales of VYZULTA as well as up to $150 million in potential future milestones.
  • Bausch + Lomb is a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC).

Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 25, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Exelixis, Cyclopropanes, Quinolines, Tyrosine kinase inhibitors, Cabozantinib, Ipsen, Royalty payment, Companies, Chemical substances

Exelixis earned $17.0 million in royalty revenues based upon Ipsens cabozantinib-related revenues in the fourth quarter of 2019.

Key Points: 
  • Exelixis earned $17.0 million in royalty revenues based upon Ipsens cabozantinib-related revenues in the fourth quarter of 2019.
  • Under the collaboration agreement with Ipsen, Exelixis received a $3.0 million milestone payment for the Health Canada approval, which was recognized as revenue in the fourth quarter of 2019.
  • Under the collaboration agreement with Ipsen, Exelixis received a $2.0 million milestone payment for the Health Canada approval, which was recognized as revenue in the fourth quarter of 2019.
  • Exelixis management will discuss the companys financial results for the fourth quarter and full year 2019 and provide a general business update during a conference call beginning at 5:00 p.m.

Exelixis Announces Webcasts of Investor Conference Presentations in February

Retrieved on: 
Thursday, February 6, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Chemical compounds, Organic compounds, Exelixis, Cyclopropanes, Quinolines, Tyrosine kinase inhibitors, Cabozantinib, Midcap, Cobimetinib, Twitter

Guggenheim Healthcare Talks Oncology Day: Exelixis is scheduled to present at 9:00 AM EST / 6:00 AM PST on Thursday, February 13, 2020 in New York.

Key Points: 
  • Guggenheim Healthcare Talks Oncology Day: Exelixis is scheduled to present at 9:00 AM EST / 6:00 AM PST on Thursday, February 13, 2020 in New York.
  • Exelixis is a member of Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.

Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma

Retrieved on: 
Wednesday, January 29, 2020
Oncology, FDA, Health, Clinical trials, General Health, Pharmaceutical, Clinical medicine, Medicine, Cyclopropanes, Quinolines, Tyrosine kinase inhibitors, Cabozantinib, Exelixis, Ipsen, Tyrosine kinase receptors, Renal cell carcinoma, Branches of biology, C-Met, HCC, CABOMETYX® (cabozantinib)

In April 2019, Takeda applied for approval to manufacture and sell cabozantinib as a treatment for unresectable and metastatic renal cell carcinoma (RCC) in Japan.

Key Points: 
  • In April 2019, Takeda applied for approval to manufacture and sell cabozantinib as a treatment for unresectable and metastatic renal cell carcinoma (RCC) in Japan.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan.
  • Do not administer CABOMETYX to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.

Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease

Retrieved on: 
Tuesday, January 28, 2020
Cyclopropanes

This completes patient enrollment in a randomized, double-blind, placebo-controlled, Phase 2b study of PTI-125, Cassava Sciences investigational drug to treat Alzheimers disease.

Key Points: 
  • This completes patient enrollment in a randomized, double-blind, placebo-controlled, Phase 2b study of PTI-125, Cassava Sciences investigational drug to treat Alzheimers disease.
  • Our previously announced results of a Phase 2a study with PTI-125 generated promising biomarker data in Alzheimers patients.
  • Phase 2b is a randomized, double-blind, placebo-controlled, multi-center study of PTI-125 in patients with mild-to-moderate Alzheimer's disease in the United States.
  • Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimers disease.

IntelGenx Announces Pricing of Equity Offering

Retrieved on: 
Monday, January 27, 2020
Chemical compounds, Organic compounds, Chloroarenes, Cyclopropanes, Montelukast, Quinolines, RTT, Thioethers

The Offering is being conducted on a commercially reasonable best efforts basis by Echelon Wealth Partners Inc. (the Agent) in the provinces of British Columbia, Alberta, Manitoba and Ontario.

Key Points: 
  • The Offering is being conducted on a commercially reasonable best efforts basis by Echelon Wealth Partners Inc. (the Agent) in the provinces of British Columbia, Alberta, Manitoba and Ontario.
  • Closing of the Offering is expected to occur on or about February11, 2020.
  • The net proceeds from the Offering will be used for the Companys Phase 2A Montelukast Study and general working capital requirements.
  • IntelGenx is a drug delivery company focused on the development and manufacturing of pharmaceutical films.